Session » SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0281

ANCA in SLE: Prevalence and Predictor Factors

9:00AM-11:00AM: Abstract Number: 0257

Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records

9:00AM-11:00AM: Abstract Number: 0248

Assessment of Lupus Knowledge Through Creation of the Lupus Knowledge Assessment Test (LKAT)

9:00AM-11:00AM: Abstract Number: 0242

Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0280

Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application

9:00AM-11:00AM: Abstract Number: 0252

Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis

9:00AM-11:00AM: Abstract Number: 0260

Does Higher Quality of Care in SLE Improve Quality of Life?

9:00AM-11:00AM: Abstract Number: 0251

Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort

9:00AM-11:00AM: Abstract Number: 0255

Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint

9:00AM-11:00AM: Abstract Number: 0265

Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort

9:00AM-11:00AM: Abstract Number: 0271

External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0246

Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms

9:00AM-11:00AM: Abstract Number: 0263

Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0267

Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?

9:00AM-11:00AM: Abstract Number: 0259

Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 0268

Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 0277

Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria

9:00AM-11:00AM: Abstract Number: 0254

LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort

9:00AM-11:00AM: Abstract Number: 0247

Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0250

Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience

9:00AM-11:00AM: Abstract Number: 0273

Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia

9:00AM-11:00AM: Abstract Number: 0275

Paradoxical Relationship Between Disease Activity and Satisfaction with Care in Lupus

9:00AM-11:00AM: Abstract Number: 0256

Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 0261

Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 0264

Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0279

Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0253

Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0262

SLE Pregnancies: C4 as Predictor of Flares and Adverse Pregnancy Outcomes

9:00AM-11:00AM: Abstract Number: 0272

Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold

9:00AM-11:00AM: Abstract Number: 0245

Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record

9:00AM-11:00AM: Abstract Number: 0269

Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality

9:00AM-11:00AM: Abstract Number: 0266

The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0270

The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE

9:00AM-11:00AM: Abstract Number: 0274

The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades

9:00AM-11:00AM: Abstract Number: 0243

The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus

9:00AM-11:00AM: Abstract Number: 0278

Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 0276

Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy

9:00AM-11:00AM: Abstract Number: 0258

Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 0249

Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients

9:00AM-11:00AM: Abstract Number: 0244

What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].